DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0256616 A1 Hsu (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0256616 A1 Hsu (43) Pub US 2014025,6616A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0256616 A1 Hsu (43) Pub. Date: Sep. 11, 2014 (54) MODIFIED GREEN TEA POLYPHENOL Publication Classification FORMULATIONS (51) Int. Cl. (71) Applicant: Georgia Regents Research Institute, A613 L/353 (2006.01) Inc., Augusta, GA (US) A638/2 (2006.01) A63/546 (2006.01) (72) Inventor: Stephen D. Hsu, Evans, GA (US) A613 L/7036 (2006.01) A613 L/7048 (2006.01) A613 L/496 (2006.01) (73) Assignee: Georgia Regents Research Institute, A61E36/82 (2006.01) Inc., Augusta, GA (US) A613 L/43 (2006.01) A613 L/65 (2006.01) 52) U.S. C. (21) Appl. No.: 14/280,805 (52) CPC ............... A61 K3I/353 (2013.01); A61K 31/43 (2013.01); A61 K38/12 (2013.01); A61 K (22) Filed: May 19, 2014 3 1/546 (2013.01); A61 K3I/65 (2013.01); A6 IK3I/7048 (2013.01); A61 K3I/496 O O (2013.01); A61 K36/82 (2013.01); A61 K Related U.S. Application Data 3/7036 (2013.01) (63) Continuation of application No. 13/305,296, filed on USPC ............ 514/2.9; 514/456; 514/198: 514/202; Nov. 28, 2011, which is a continuation of application 514/154: 514/29: 514/254.11: 514/37 No. 12/063,139, filed on Feb. 7, 2008, now Pat No. (57) ABSTRACT 8,076.484, filed as application No. PCT/US06/31120 Modified green tea polyphenols and methods of their use are on Aug. 10, 2006. provided. One aspect provides compounds and compositions (60) Provisional application No. 60/707,234, filed on Aug. containing green tea polyphenols with one on more ester 11, 2005. linked fatty acids. US 2014/025661.6 A1 Sep. 11, 2014 MODIFIED GREEN TEA POLYPHENOL or ketoconazole as active ingredients. Salicylic acid helps FORMULATIONS dissolve skin flakes. Pyrithione helps to kill fungus. Coal tar is believed to help reduce inflammation and sebum and to CROSS-REFERENCE TO RELATED prevent the reoccurrence of flakes and scalp build-up. Coaltar APPLICATION is a combination of compounds produced from by-products 0001. This application is a continuation of U.S. Ser. No. of coal distillation, and a number of studies report that coal tar 13/305,296 filed Nov. 28, 2011, which is a continuation of is toxic or carcinogenic. For example, coal tar contains benzo U.S. Ser. No. 12/063,139 filed Feb. 7, 2008, issued U.S. Pat. apyrene, a highly potent carcinogen. Studies have shown No. 8,076,484, which is a national phase filing under 35 that topical application of compositions containing coal tar U.S.C. S371 of PCT/US2006/031120 filed under the Patent are toxic and may cause DNA damage (Thein, N. etal. (2000) Cooperation Treaty on Aug. 10, 2006, which claims benefit of Muta Res 468(2): 117-24; Rojas, M. etal. (2001) Carcinogen and priority to U.S. Provisional Patent Application No. esis 22(7): 1015-8; Vogel, U. et al. (2001) Pharmacol Toxicol. 60/707,234 filed Aug. 11, 2005, all of which are incorporated 89(1):30-4). herein by reference in their entirety. 0010 Green tea polyphenols are known phytochemicals that have antioxidant, anti-microbial, anticancer, and anti TECHNICAL FIELD inflammation properties, and were recently found to promote 0002 Aspects of the disclosure are generally related to skin homeostasis and protect against autoimmune diseases. green tea polyphenol compositions, more particularly, to Extracts of green tea have been used for medicinal purposes lipid-soluble green tea polyphenol compositions. for generations in China. Green tea polyphenols in extracts are mostly water-soluble, and can be easily oxidized if they BACKGROUND are mixed in emulsions containing water, such as detergents and cosmetics. Additionally, conventional green tea polyphe 0003 More than 15 million people in the U.S. have symp nols are not permeable to the skin, and therefore their activity toms of a skin disorder, for example dermatitis. Dermatitis is is significantly reduced. a term literally meaning “inflammation of the skin'. It is usually used to refer to eczema, and several different forms 0011 Thus, there is a need for additional green tea are recognized including cercarial dermatitis, dermatitis her polyphenol compositions and methods for preventing and petiformis, atopic dermatitis, seborrhoeic dermatitis, and treating skin disorders or symptoms thereof. contact dermatitis. 0004 Cercarial dermatitis is a short-term, immune reac SUMMARY tion occurring in the skin of humans that have been infected by water-borne trematode parasites. Symptoms, which 0012 Aspects of the disclosure generally provide modi include itchy, raised papules, commonly occur within hours fied green tea polyphenol compositions having one or more of infection and do not generally last more than a week. ester-linked C to Clso fatty acids or hydrocarbons. Choles 0005 Dermatitis herpetiformis (DH) or Duhring's Dis terol can also be linked to green tea polyphenols via an ether ease, is a skin disorder often associated with celiac disease. It linkage. Green tea polyphenols that can be modified include, is a chronic, extremely itchy rash consisting of papules and but are not limited to (-)-epicatechin (EC), (-)-epigallocat vesicles. Dermatitis herpetiformis is associated with sensitiv echin (EGC), (-)-epicatechin-3-gallate (ECF), (-)-epigallo ity of the intestine to gluten in the diet. catechin-3-gallate (EGCG), proanthocyanidins, enantiomers 0006 Atopic dermatitis, sometimes called eczema, is a thereof, epimers thereof, isomers thereof, combinations kind of dermatitis, an atopic skin disease. Skin of an affected thereof, and prodrugs thereof. The modified green tea person reacts to irritants, food and air allergens and becomes polyphenols are more lipid-soluble than unmodified green tea red, flaky and very itchy. It also becomes vulnerable to polyphenols. It is believed that the increased lipid solubility inflammations caused by bacteria. Atopic dermatitis very increases the bioavailability of the green tea polyphenols and often occurs together with otheratopic diseases like hay fever, thereby increases the effectiveness of the green tea polyphe asthma and conjunctivitis. nols. Green tea polyphenols are known to modulate gene 0007 Seborrheic dermatitis is a disease that causes flaking expression and have been used in the treatment of cancer. of the skin. It particularly affects the sebum-gland rich areas 0013 One aspect provides a compound according to For of skin. It can also affect the face and chest, and the creases of mula I: the arms, legs and groin. Seborrheic dermatitis usually causes the skin to look a little greasy and scaly or flaky. It is thought to be caused by a fungal infection caused by the yeast Formula I Malassezia furfur in individuals with decreased immunity and increased sebum production. 0008 Domestic pets and animals also suffer from skin disorders including atopic dermatitis. Atopic dermatitis is one of the most common skin diseases of dogs. As with humans, the principal causes of atopic dermatitis are external aller gens, e.g., house dust mites, pollens, molds, etc. Treatments include allergen avoidance and prevention of allergen con tact, symptomatic anti-inflammatory pharmacotherapy, aller gen-specific immunotherapy, and antimicrobial therapy. 0009 Topical treatments for seborrheic dermatitis include shampoos containing coal tar, Zinc pyrithione, salicylic acid US 2014/025661.6 A1 Sep. 11, 2014 wherein R. R. R. R. Rs are each independently H, OH, 0022 wherein R is not O O O -o-I-R. or -C-O-R: -o-Itchhi-ch when R. R. R. R7, Rs. Ro, and Ro are OH: 0014 wherein R, is a linear, branched or cyclic, saturated 0023 wherein at least one of R. R. R. R. R. R. or Rio or unsaturated. Substituted or unsubstituted C-C group, is wherein if R is cyclic, R, is a C-C group; and 0015 R is O. —NRR, or S, wherein Rs and R are independently hydrogen, or a linear, branched, or cyclic, Satu O rated or unsaturated, Substituted or unsubstituted C-Clso -o-I-R, or -C-O-R; group, wherein if Rs and/or R are cyclic, Rs and/or Ro are C-Clso groups; 0024 or a pharmaceutically acceptable salt or prodrug 0016 wherein at least one of R. R. R. R. Rs is thereof. 0025. Another aspect provides a compound according to Formula II: O -o-I-R. or -C-O-R7; Formula II R3 0017 or a pharmaceutically acceptable salt or prodrug R4 thereof. 0018. Another aspect provides a compound according to R R6 Formula II: R. Rs Rs R9 Formula II R2 O R3 R10 R4 0026 wherein R. R. R. R. R. Rs. Ro, and Ro are each R R independently H, OH, 6 R R8 O O Rs R9 -o-I-R, or -C-O-R; R O R10 0027 R is a linear, branched, or cyclic, saturated or unsaturated, Substituted or unsubstituted C-Clso group, 0.019 wherein R. R. R. R. R. Rs. Ro, and Ro are each wherein if R is cyclic, R is a C-Clso group; independently H, OH, 0028 Rs and R are independently O. —NR,R or S, wherein R and Rs are independently hydrogen, or a linear, branched, or cyclic, saturated or unsaturated, Substituted or unsubstituted C-Clso group, wherein if R and/or R are O O cyclic, R12 and/or Rs are Cs-Cao groups; -o-I-R, or -C-O-R; 0029 wherein at least two of R. R. R. R. R. R. R. or Ro are 0020 R is a linear, branched, or cyclic, saturated or unsaturated, Substituted or unsubstituted C-Clso group, O O wherein if R is cyclic, R is a C-Clso group; -o-I-R, or -C-O-R; 0021 Rs and R are independently O.
Load more

Recommended publications
  • B-Lactams: Chemical Structure, Mode of Action and Mechanisms of Resistance
    b-Lactams: chemical structure, mode of action and mechanisms of resistance Ru´ben Fernandes, Paula Amador and Cristina Prudeˆncio This synopsis summarizes the key chemical and bacteriological characteristics of b-lactams, penicillins, cephalosporins, carbanpenems, monobactams and others. Particular notice is given to first-generation to fifth-generation cephalosporins. This review also summarizes the main resistance mechanism to antibiotics, focusing particular attention to those conferring resistance to broad-spectrum cephalosporins by means of production of emerging cephalosporinases (extended-spectrum b-lactamases and AmpC b-lactamases), target alteration (penicillin-binding proteins from methicillin-resistant Staphylococcus aureus) and membrane transporters that pump b-lactams out of the bacterial cell. Keywords: b-lactams, chemical structure, mechanisms of resistance, mode of action Historical perspective Alexander Fleming first noticed the antibacterial nature of penicillin in 1928. When working with Antimicrobials must be understood as any kind of agent another bacteriological problem, Fleming observed with inhibitory or killing properties to a microorganism. a contaminated culture of Staphylococcus aureus with Antibiotic is a more restrictive term, which implies the the mold Penicillium notatum. Fleming remarkably saw natural source of the antimicrobial agent. Similarly, under- the potential of this unfortunate event. He dis- lying the term chemotherapeutic is the artificial origin of continued the work that he was dealing with and was an antimicrobial agent by chemical synthesis [1]. Initially, able to describe the compound around the mold antibiotics were considered as small molecular weight and isolates it. He named it penicillin and published organic molecules or metabolites used in response of his findings along with some applications of penicillin some microorganisms against others that inhabit the same [4].
    [Show full text]
  • Multi-Residual Quantitative Analytical Method for Antibiotics in Sea Food by LC/MS/MS
    PO-CON1742E Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS ASMS 2017 TP 198 Anant Lohar, Shailendra Rane, Ashutosh Shelar, Shailesh Damale, Rashi Kochhar, Purushottam Sutar, Deepti Bhandarkar, Ajit Datar, Pratap Rasam and Jitendra Kelkar Shimadzu Analytical (India) Pvt. Ltd., 1 A/B, Rushabh Chambers, Makwana Road, Marol, Andheri (E), Mumbai-400059, Maharashtra, India. Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS Introduction Antibiotics are widely used in agriculture as growth LC/MS/MS method has been developed for quantitation of enhancers, disease treatment and control in animal feeding multi-residual antibiotics (Table 1) from sea food sample operations. Concerns for increased antibiotic resistance of using LCMS-8040, a triple quadrupole mass spectrometer microorganisms have prompted research into the from Shimadzu Corporation, Japan. Simultaneous analysis environmental occurrence of these compounds. of multi-residual antibiotics often exhibit peak shape Assessment of the environmental occurrence of antibiotics distortion owing to their different chemical nature. To depends on development of sensitive and selective overcome this, autosampler pre-treatment feature was analytical methods based on new instrumental used [1]. technologies. Table 1. List of antibiotics Sr.No. Name of group Name of compound Number of compounds Flumequine, Oxolinic Acid, Ciprofloxacin, Danofloxacin, Difloxacin.HCl, 1 Fluoroquinolones 8 Enrofloxacin, Sarafloxacin HCl Trihydrate,
    [Show full text]
  • Download (12Mb)
    A Thesis Submitted for the Degree of PhD at the University of Warwick Permanent WRAP URL: http://wrap.warwick.ac.uk/110352 Copyright and reuse: This thesis is made available online and is protected by original copyright. Please scroll down to view the document itself. Please refer to the repository record for this item for information to help you to cite it. Our policy information is available from the repository home page. For more information, please contact the WRAP Team at: [email protected] warwick.ac.uk/lib-publications THE BRITISH LIBRARY BRITISH THESIS SERVICE THE DISTRIBUTION OF PHENOTYPIC AND GENOTYPIC CHARACTERS WITHIN STREPTOMYCETES AND THEIR RELATIONSHIP TITLE . TO ANTIBIOTIC PRODUCTION. AUTHOR........ Lesley Phillips, DEGREE.................................................... AWARDING BODY _ TI. .. The University of Warwick, THESIS NUMBER THIS THESIS HAS BEEN MICROFILMED EXACTLY AS RECEIVED The quality of this reproduction is dependent upon the quality of the original thesis submitted for microfilming. Every effort has been made to ensure the highest quality of reproduction. Some pages may have indistinct print, especially if the original papers were poorly produced or if the awarding body sent an inferior copy. If pages are missing, please contact the awarding body which granted the degree. Previously copyrighted materials (journal articles, published texts, etc.) are not filmed. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that Its copyright rests with its author and that no information derived from it may be published without the author's prior written consent. Reproduction of this thesis, other than as permitted under the United Kingdom Copyright Designs and Patents Act 1988, or under specific agreement with the copyright holder, is prohibited.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Mitigation of Antimicrobial Drug Resistance and Changes in The
    Mitigation of Antimicrobial Drug Resistance and Changes in the Microbiome of Feedlot Cattle Supplemented with Lactobacillus salivarius L28 as an Alternative to Sub-Therapeutic Antibiotics by Andrea R. English, M.S. A Dissertation In Animal Science Submitted to the Graduate Faculty of Texas Tech University in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Approved Dr. Marcos X. Sánchez-Plata Co-Chair of Committee Dr. Mindy M. Brashears Co-Chair of Committee Dr. Kendra K. Nightingale Dr. Alejandro Echeverry Dr. Jessie Vipham Dr. Mark F. Miller Mark Sheridan Dean of the Graduate School December, 2019 Copyright 2019, Andrea English Texas Tech University, Andrea English, December 2019 ACKNOWLEDGMENTS I would like to first thank my advisor Dr. Mindy Brashears you took a chance on me and I am forever grateful. I am so thankful that I was able to learn and grow as a scientist under your guidance. You have provided me with experiences I will always remember. Thank you for everything you have done for me while at Texas Tech. Thank you to my committee, Dr. Sanchez you have been an incredible mentor and I have truly valued absorbing as much knowledge as I possibly could from you. Dr. Nightingale thank you for investing in me and this project. You pushed me to be a better scientist which I very much appreciate. Dr. Echeverry and Dr. Vipham I cannot say thank you enough for the support you have provided me. You each have always made time for me and that is invaluable. Dr. Miller thank you for continuously providing me with opportunities to grow, learn and dabble in meat science while here at Texas Tech.
    [Show full text]
  • Antibiotic Discovery
    ANTIBIOTIC DISCOVERY RESISTANCE PROFILING OF MICROBIAL GENOMES TO REVEAL NOVEL ANTIBIOTIC NATURAL PRODUCTS By CHELSEA WALKER, H. BSc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the Degree Master of Science McMaster University © Copyright by Chelsea Walker, May 2017 McMaster University MASTER OF SCIENCE (2017) Hamilton, Ontario (Biochemistry and Biomedical Sciences) TITLE: Resistance Profiling of Microbial Genomes to Reveal Novel Antibiotic Natural Products. AUTHOR: Chelsea Walker, H. BSc. (McMaster University) SUPERVISOR: Dr. Nathan A. Magarvey. COMMITTEE MEMBERS: Dr. Eric Brown and Dr. Michael G. Surette. NUMBER OF PAGES: xvii, 168 ii Lay Abstract It would be hard to imagine a world where we could no longer use the antibiotics we are routinely being prescribed for common bacterial infections. Currently, we are in an era where this thought could become a reality. Although we have been able to discover antibiotics in the past from soil dwelling microbes, this approach to discovery is being constantly challenged. At the same time, the bacteria are getting smarter in their ways to evade antibiotics, in the form of resistance, or self-protection mechanisms. As such is it essential to devise methods which can predict the potential for resistance to the antibiotics we use early in the discovery and isolation process. By using what we have learned in the past about how bacteria protect themselves for antibiotics, we can to stay one step ahead of them as we continue to search for new sources of antibiotics from bacteria. iii Abstract Microbial natural products have been an invaluable resource for providing clinically relevant therapeutics for almost a century, including most of the commonly used antibiotics that are still in medical use today.
    [Show full text]
  • DNA/RNA Synthesis
    DNA/RNA Synthesis RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm. Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA. First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein. www.MedChemExpress.com 1 DNA/RNA Synthesis Inhibitors, Agonists, Activators, Modulators & Chemicals (+)-TK216 (-)-TK216 Cat. No.: HY-122903B Cat. No.: HY-122903A (+)-TK216 is an enantiomer of TK216 (HY-122903). (-)-TK216 is an enantiomer of TK216 (HY-122903). TK216 is an orally active and potent E26 TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor.
    [Show full text]
  • General Prescription
    GENERAL PRESCRIPTION LESSON 1. INTRODUCTION. PRESCRIPTION. SOLID MEDICINAL FORMS Objective: To study the structure of the prescription, learn the rules and get practical skills in writing out solid medicinal forms in prescription. To carry out practical tasks on prescriptions it is recommended to use Appendix 1. Key questions: 1. Pharmacology as a science and the basis of therapy. Main development milestones of modern pharmacology. Sections of Pharmacology. 2. The concept of medicinal substance, medicinal agent (medicinal drug, drug), medicinal form. 3. The concept of the pharmacological action and types of the action of drugs. 4. The sources of obtaining drugs. 5. International and national pharmacopeia, its content and purpose. 6. Pharmacy. Rules of drug storage and dispensing. 7. Prescription and its structure. Prescription forms. General rules for writing out a prescription. State regulation of writing out and dispensing drugs. 8. Name of medicinal products (international non-proprietary name - INN, trade name). 9. Peculiarities of writing out narcotic, poisonous and potent substances in prescription. 10. Drugs under control. Drugs prohibited for prescribing. 11. Solid medicinal forms: tablets, dragee (pills), powders, capsules. Their characteristics, advantages and disadvantages. Rules of prescribing. Write out prescriptions for: 1. 5 powders of Codeine 0.015 g. 1 powder orally twice a day. 2. 10 powders of Didanosine 0.25 g in sachets to prepare solution for internal use. Accept inside twice a day one sachet powder after dissolution in a glass of boiled water. 3. 50 mg of Alteplase powder in the bottle. Dissolve the content of the bottle in 50 ml of saline. First 15 ml introduce intravenously streamly, then intravenous drip.
    [Show full text]
  • Multi-Class Confirmatory Method for Analyzing Trace Levels of Tetracyline
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY Rapid Commun. Mass Spectrom. 2007; 21: 3487–3496 Published online in Wiley InterScience (www.interscience.wiley.com) DOI: 10.1002/rcm.3236 Multi-class confirmatory method for analyzing trace levels of tetracyline and quinolone antibiotics in pig tissues by ultra-performance liquid chromatography coupled with tandem mass spectrometry Bing Shao1,4*, Xiaofei Jia1, Yongning Wu2, Jianying Hu3, Xiaoming Tu1 and Jing Zhang1 1Beijing Center for Disease Control and Prevention, Beijing 100013, China 2Institute of Nutrition and Food Safety, China Center for Disease Control and Prevention, Beijing 100085, China 3College of Environmental Science, Peking University, Beijing 100871, China 4School of Public Health and Family Medicine, Capital Medical University, Beijing 100089, China Received 8 June 2007; Revised 26 August 2007; Accepted 27 August 2007 An ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC/MS/ MS) method was developed to screen and confirm multi-class veterinary drug residues in pig tissues including pig kidney, liver and meat. Twenty-one drugs of two different classes including seven tetracyclines and four types of quinolones (quinoline, naphthyridine, pyridopyrimidine and cino- line) were determined simultaneously in a single run. The homogenized sample tissues were extracted with EDTA–McIlvaine buffer solution and further purified using a polymer-based Oasis TM HLB solid-phase extraction (SPE) cartridge. An ACQUITY UPLC BEH C18 column was used to separate the analytes followed by tandem mass spectrometry using an electrospray ionization source. MS data acquisition was performed in the positive ion multiple reaction monitoring mode, selecting two ion transitions for each target compound. Recovery studies were performed at different fortification levels.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Safety, Tolerability and Pharmacokinetics of Intravaginal Pentamycin
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by edoc Pharmacology Chemotherapy 2010;56:190–196 Received: March 20, 2009 DOI: 10.1159/000316329 Accepted after revision: January 12, 2010 Published online: June 10, 2010 Safety, Tolerability and Pharmacokinetics of Intravaginal Pentamycin a a c b B. Frey Tirri J. Bitzer B. Geudelin J. Drewe a b Departments of Obstetrics and Gynecology, and Clinical Pharmacology, University Hospital Basel, and c Mediante GmbH, Basel , Switzerland Key Words cin does not cause adverse reactions compared with vehicle -Antimicrobial agents ؒ Pentamycin ؒ Pharmacokinetics ؒ and is not absorbed through the intact or the inflamed va Polyene antifungal antibiotic ؒ Vaginal infections gina. Copyright © 2010 S. Karger AG, Basel Abstract Background/Aims: Intravaginal pentamycin is a polyene Introduction macrolide with a broad spectrum of antimicrobial activity and is effective in various forms of infectious vaginitis. We The most common vaginal disorders include vaginal evaluated the safety, tolerability and pharmacokinetics of candidiasis, vaginal trichomoniasis and bacterial vagino- escalating doses of this product. Methods: Nineteen healthy sis [1–5] . Forms of infectious vaginitis sustained by mixed volunteers were randomized to receive double blind one of micro-organisms are also observed frequently [6] . Vagi- five doses of intravaginal pentamycin (3, 10, 30, 60 or 100 mg) nal infections can be successfully treated by using one or or the corresponding dose of pentamycin vehicle daily for more pathogen-specific antimicrobials [1, 3, 7–9] , but, be- 6 days. Patients with symptomatic vaginitis received a single fore vaginitis is treated, the cause must be ascertained by dose of 60 (n = 6) or 100 mg (n = 6) of intravaginal penta- using appropriate laboratory tests [1, 2, 6, 7, 10] .
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]